Pathway analysis showed that APOA1 serves as a hubprotein connecting PPARs and NAFLD through a beneficial modulation of 16 out of 21 NAFLD upstream regulators. This evidence concerns the gene APOA1 and metabolic dysfunction-associated steatotic liver disease.